Moderation of the daily dose of HRT

Benefits for patients

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: Hormone replacement therapy (HRT) has many benefits yet compliance rates remain low. One of the main reasons for discontinuing therapy is hyperestrogenic side effects which may be dose related, and the initiation of treatment is critical to a patient's chances of gaining long-term benefits. The introduction of low dose HRT means that physicians have an option to initiate or titrate patients to a low dose. The purpose of this review is to examine current literature on the benefits for patients of low dose HRT. Results: Low dose estrogen (25 mcg/day transdermally or 0.3 mg/day orally) are effective in controlling postmenopausal symptoms, reducing bone loss and reducing cardiovascular risk factors. Low dose therapy is also effective at reducing vasomotor symptoms in highly symptomatic women. In one study, patients on a daily dose of 25 mcg estrogen experienced an 86% reduction in vasomotor symptoms compared to a 55% reduction in patients on placebo. In addition, many adverse events related to estrogens were reduced using a low dose. Conclusion: Compliance with traditional doses of HRT is currently a problem for many women who may stop taking therapy because they experience hyperestrogenic side effects. Low dose HRT is effective at reducing vasomotor symptoms and controlling symptoms even in highly symptomatic women. Hyperestrogenic side effects may be reduced by initiating treatment at the lowest dose and titrating upwards if necessary. This may have benefits for patients in terms of offering effective control of symptoms whilst minimising hyperestrogenic effects. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)25-29
Number of pages5
JournalMaturitas
Volume33
Issue numberSUPPL. 1
DOIs
StatePublished - Nov 1999
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Hormones
Estrogens
Therapeutics
Bone
Placebos
Physicians
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Aging
  • Obstetrics and Gynecology

Cite this

Moderation of the daily dose of HRT : Benefits for patients. / Schneider, H. P G; Gallagher, John Christopher G.

In: Maturitas, Vol. 33, No. SUPPL. 1, 11.1999, p. 25-29.

Research output: Contribution to journalArticle

Schneider, H. P G ; Gallagher, John Christopher G. / Moderation of the daily dose of HRT : Benefits for patients. In: Maturitas. 1999 ; Vol. 33, No. SUPPL. 1. pp. 25-29.
@article{5d1b0169f4a44cf5a367962ceeef0c99,
title = "Moderation of the daily dose of HRT: Benefits for patients",
abstract = "Introduction: Hormone replacement therapy (HRT) has many benefits yet compliance rates remain low. One of the main reasons for discontinuing therapy is hyperestrogenic side effects which may be dose related, and the initiation of treatment is critical to a patient's chances of gaining long-term benefits. The introduction of low dose HRT means that physicians have an option to initiate or titrate patients to a low dose. The purpose of this review is to examine current literature on the benefits for patients of low dose HRT. Results: Low dose estrogen (25 mcg/day transdermally or 0.3 mg/day orally) are effective in controlling postmenopausal symptoms, reducing bone loss and reducing cardiovascular risk factors. Low dose therapy is also effective at reducing vasomotor symptoms in highly symptomatic women. In one study, patients on a daily dose of 25 mcg estrogen experienced an 86{\%} reduction in vasomotor symptoms compared to a 55{\%} reduction in patients on placebo. In addition, many adverse events related to estrogens were reduced using a low dose. Conclusion: Compliance with traditional doses of HRT is currently a problem for many women who may stop taking therapy because they experience hyperestrogenic side effects. Low dose HRT is effective at reducing vasomotor symptoms and controlling symptoms even in highly symptomatic women. Hyperestrogenic side effects may be reduced by initiating treatment at the lowest dose and titrating upwards if necessary. This may have benefits for patients in terms of offering effective control of symptoms whilst minimising hyperestrogenic effects. Copyright (C) 1999 Elsevier Science Ireland Ltd.",
author = "Schneider, {H. P G} and Gallagher, {John Christopher G.}",
year = "1999",
month = "11",
doi = "10.1016/S0378-5122(99)00060-2",
language = "English",
volume = "33",
pages = "25--29",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Moderation of the daily dose of HRT

T2 - Benefits for patients

AU - Schneider, H. P G

AU - Gallagher, John Christopher G.

PY - 1999/11

Y1 - 1999/11

N2 - Introduction: Hormone replacement therapy (HRT) has many benefits yet compliance rates remain low. One of the main reasons for discontinuing therapy is hyperestrogenic side effects which may be dose related, and the initiation of treatment is critical to a patient's chances of gaining long-term benefits. The introduction of low dose HRT means that physicians have an option to initiate or titrate patients to a low dose. The purpose of this review is to examine current literature on the benefits for patients of low dose HRT. Results: Low dose estrogen (25 mcg/day transdermally or 0.3 mg/day orally) are effective in controlling postmenopausal symptoms, reducing bone loss and reducing cardiovascular risk factors. Low dose therapy is also effective at reducing vasomotor symptoms in highly symptomatic women. In one study, patients on a daily dose of 25 mcg estrogen experienced an 86% reduction in vasomotor symptoms compared to a 55% reduction in patients on placebo. In addition, many adverse events related to estrogens were reduced using a low dose. Conclusion: Compliance with traditional doses of HRT is currently a problem for many women who may stop taking therapy because they experience hyperestrogenic side effects. Low dose HRT is effective at reducing vasomotor symptoms and controlling symptoms even in highly symptomatic women. Hyperestrogenic side effects may be reduced by initiating treatment at the lowest dose and titrating upwards if necessary. This may have benefits for patients in terms of offering effective control of symptoms whilst minimising hyperestrogenic effects. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - Introduction: Hormone replacement therapy (HRT) has many benefits yet compliance rates remain low. One of the main reasons for discontinuing therapy is hyperestrogenic side effects which may be dose related, and the initiation of treatment is critical to a patient's chances of gaining long-term benefits. The introduction of low dose HRT means that physicians have an option to initiate or titrate patients to a low dose. The purpose of this review is to examine current literature on the benefits for patients of low dose HRT. Results: Low dose estrogen (25 mcg/day transdermally or 0.3 mg/day orally) are effective in controlling postmenopausal symptoms, reducing bone loss and reducing cardiovascular risk factors. Low dose therapy is also effective at reducing vasomotor symptoms in highly symptomatic women. In one study, patients on a daily dose of 25 mcg estrogen experienced an 86% reduction in vasomotor symptoms compared to a 55% reduction in patients on placebo. In addition, many adverse events related to estrogens were reduced using a low dose. Conclusion: Compliance with traditional doses of HRT is currently a problem for many women who may stop taking therapy because they experience hyperestrogenic side effects. Low dose HRT is effective at reducing vasomotor symptoms and controlling symptoms even in highly symptomatic women. Hyperestrogenic side effects may be reduced by initiating treatment at the lowest dose and titrating upwards if necessary. This may have benefits for patients in terms of offering effective control of symptoms whilst minimising hyperestrogenic effects. Copyright (C) 1999 Elsevier Science Ireland Ltd.

UR - http://www.scopus.com/inward/record.url?scp=0032711466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032711466&partnerID=8YFLogxK

U2 - 10.1016/S0378-5122(99)00060-2

DO - 10.1016/S0378-5122(99)00060-2

M3 - Article

VL - 33

SP - 25

EP - 29

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - SUPPL. 1

ER -